Today in Medicine: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Today in Medicine.

Press releases published on September 30, 2026

9 hours ago

Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States

Indeterminate GlobeNewswire

9 hours ago

Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis

Indeterminate GlobeNewswire

9 hours ago

Immutep Receives ~A$0.86 Million R&D Tax Incentive

Indeterminate GlobeNewswire

9 hours ago

Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences

Indeterminate GlobeNewswire

9 hours ago

BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Indeterminate GlobeNewswire

9 hours ago

Avacta Group plc: Interim Results for the Six Months to June 30, 2026, and Business Update

Indeterminate GlobeNewswire

9 hours ago

MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy

Indeterminate GlobeNewswire

9 hours ago

CURE ALZHEIMER’S FUND AWARDS $6.4 MILLION TO CARDINAL FAMILY SCHOLARS ADVANCING ALZHEIMER’S RESEARCH

Indeterminate GlobeNewswire

10 hours ago

Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development

Indeterminate GlobeNewswire

10 hours ago

Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings

Indeterminate GlobeNewswire

10 hours ago

Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy

Indeterminate GlobeNewswire

10 hours ago

Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

Indeterminate GlobeNewswire

10 hours ago

Ocugen to Participate in Upcoming Scientific Conferences

Indeterminate GlobeNewswire

10 hours ago

R1 Therapeutics expands Series A to $80.5 million to advance global Phase 2b program in hyperphosphatemia

Indeterminate GlobeNewswire

10 hours ago

EVerZom successfully completes CTA-enabling preclinical studies of EVerGel™ required to support a clinical trial application

Indeterminate GlobeNewswire

10 hours ago

More Than 1,600 Participants Anchor Calroy Health Sciences' Joint Formulation Research

Indeterminate GlobeNewswire

10 hours ago

Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations

Indeterminate GlobeNewswire

10 hours ago

Pharmazz, Inc. Receives U.S. FDA IND Clearance to Initiate Phase 3 Clinical Trial of Sovateltide in Traumatic Brain Injury

Indeterminate GlobeNewswire

10 hours ago

Rafael Holdings Announces Topline Results from the Pivotal Phase 3 TransportNPC™ Study of Trappsol® Cyclo™ in Niemann-Pick Disease Type C (NPC)

Indeterminate GlobeNewswire

10 hours ago

Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy

Indeterminate GlobeNewswire